September 13th, 2024
Description
The care of patients with hematologic disorders is changing rapidly as new therapies are brought forward for clinical study, and then approved by the FDA. Recent advances in leukemia, lymphoma, myeloma, sickle cell disease, blood and marrow transplant, and cellular therapy ensure that a practice gap is created for care providers not specializing in these areas. Many healthcare providers are responsible for treating large fields of oncology, or general internal medicine, and the new therapeutic options in their scope can be overwhelming. This symposium aims to educate healthcare professionals on the most important advances in the past year.
For pricing information, see pricing tab below.
Dates and Times
Start: 9/13/2024 9:00 AM
End: 9/13/2024 4:00 PM
Objectives
- Describe evidence based therapies for the treatment of benign and malignant hematological diseases
- Describe the use of biomarkers in the diagnosis of hematological diseases
- Describe factors that may require early interventions in patients with hematological diseases
- List risk factors for disease severity, morbidity, and mortality
- Explain mechanisms of actions and risks associated with novel hematological treatments
Agenda
.png)
Pricing
| Tier | Price |
|---|---|
| Non-OSU MD, DO and PhD | $100.00 |
| OSU Faculty/Staff (Division of Hematology) | $0.00 |
| OSU Faculty/Staff (Outside Division of Hematology) | $50.00 |
| Residents/Students/Fellows | $0.00 |
| All other Professionals | $125.00 |
Location
The Blackwell
2110 Tuttle Park Pl.
Columbus, OH 43210
Accreditation Statement
The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Ohio State University designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.